联检胃癌患者血清CA19-9、可溶性Fas、sFasL的临床意义

目的：通过联检胃癌患者手术前后血清CA19—9和sFas、sFasL水平变化，探讨其在胃癌早期诊断及复发判断的临床意义。方法：采用电化学发光免疫和ELLSA检测40例胃癌患者手术前后血清CA19—9和sFas、sFasL的含量，并与40例健康体检者进行比较。结果：①胃癌患者手术前后血清CA19—9和sFas、sFasL水平比较有显著差异（P〈0．05）。②胃癌手术前血清CA19—9和sFas、sFasL水平与对照组比较有显著差异（P〈0．05）。③手术成功后CA125和sFasL水平与对照组比较无显著差异（P〉0．05）。结论：①sFas、sFasL的高表达与胃癌的发生、发展密切相关；②sFas、sFasL尤其是sFasL可作为胃癌早期诊断新的血清学诊断标志物，与CA19—9联检，对胃癌患者的疗效观察和复发判断有重要的指导意义。

Clinical Significance of Combined Determination of Serum CA19-9, Soluble Fas and Soluble Fas Ligand (sFasL) in Patients with Gastric Carcinoma

Objective To study the clinical usefulness of combined determination of serum CA19-9,sFas and sFasL for early diagnosis and diseases assessment in patients with gastric carcinoma.Methods Serum CA19-9(with CLIA) and sFas,sFasL(with ELISA) levels were measured both before and after operation in 40 patients with gastric carcinoma as well as 40 controls.Results Serum CA19-9,sFas and sFasL levels in the patients before operation were significantly higher than those in controls(P<0.05).After resection of the tumors,the serum levels in the patients dropped markedly and were not much different from those in controls(P>0.05).Conclusion Serum sFas and sFasL levels in creased very significantly preoperatively in patients with gastric carcinoma combined determination of serum levels of sFas and sFasL with CA19-9 could improve early diagnosis.